Guidance Lowered Yet 9% Surge... Focus on Earnings

On May 5, Revvity Inc. (NYSE: RVTY) surged 8.82%, closing at $94.14 on the New York Stock Exchange, which added roughly $1 billion to its market capitalization—about ₩1.4 trillion—in a single session. Trading volume topped 1.1 million shares, signaling a clear uptick in investor demand.

On the same day, Revvity reported first-quarter fiscal 2026 revenue of $710 million and adjusted EPS of $1.06, slightly above market expectations, and announced plans to divest its China immunodiagnostics business. It issued conservative guidance for fiscal 2026—projecting EPS of $5.20–$5.30 and revenue around $2.8 billion. Despite the guidance falling short of consensus, investors viewed the company’s defensive earnings profile and portfolio repositioning positively, driving an “earnings surprise” rally.

Headquartered in Waltham, Massachusetts, Revvity is a life-sciences and diagnostic-equipment provider spun off from PerkinElmer in 2023. It supplies gene and cell analysis instruments as well as neonatal and infectious-disease diagnostic kits. The company is regarded as a mid-cap growth stock, underpinned by relatively stable healthcare demand amid economic cycles, and has spent recent years divesting non-core assets and restructuring to enhance profitability.